Join Growin Stock Community!

Cumberland pharmaceuticals inc.CPIX.US Overview

US StockHealthcare
(No presentation for CPIX)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

CPIX AI Insights

CPIX Overall Performance

CPIX AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

CPIX Recent Performance

1.22%

Cumberland pharmaceuticals inc.

0.05%

Avg of Sector

-0.31%

S&P500

CPIX PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

CPIX Key Information

CPIX Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

CPIX Profile

Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, rheumatology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of chronic and acute constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections. It also develops RediTrex injection for the treatment of active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, as well as disabling psoriasis. In addition, the company is developing ifetroban, a product candidate that is in phase II clinical trial for the treatment of aspirin-exacerbated respiratory disease, systemic sclerosis, and duchenne muscular dystrophy; and has completed phase II clinical trial for the treatment of hepatorenal syndrome and portal hypertension. Further, it develops a clinical program for the use of ifetroban to treat progressive fibrosing interstitial lung diseases; and a product candidate that is in Phase II clinical trial for cholesterol reducing agent to use in the hospital setting. The company was incorporated in 1999 and is headquartered in Nashville, Tennessee.

Price of CPIX

CPIX FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

CPIX Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.22
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
1.78
PB Ratio
2.57
Price-to-FCF
14.27
METRIC
VALUE
vs. INDUSTRY
Gross Margin
84.49%
Net Margin
-8.06%
Revenue Growth (YoY)
12.21%
Profit Growth (YoY)
13.80%
3-Year Revenue Growth
-10.10%
3-Year Profit Growth
-7.37%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.22
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
1.78
PB Ratio
2.57
Price-to-FCF
14.27
Gross Margin
84.49%
Net Margin
-8.06%
Revenue Growth (YoY)
12.21%
Profit Growth (YoY)
13.80%
3-Year Revenue Growth
-10.10%
3-Year Profit Growth
-7.37%

  • When is CPIX's latest earnings report released?

    The most recent financial report for Cumberland pharmaceuticals inc. (CPIX) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating CPIX's short-term business performance and financial health. For the latest updates on CPIX's earnings releases, visit this page regularly.

  • What is the operating profit of CPIX?

    According to the latest financial report, Cumberland pharmaceuticals inc. (CPIX) reported an Operating Profit of -1.97M with an Operating Margin of -23.7% this period, representing a decline of 15.98% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is CPIX's revenue growth?

    In the latest financial report, Cumberland pharmaceuticals inc. (CPIX) announced revenue of 8.29M, with a Year-Over-Year growth rate of -8.73%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much debt does CPIX have?

    As of the end of the reporting period, Cumberland pharmaceuticals inc. (CPIX) had total debt of 10.24M, with a debt ratio of 0.16. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does CPIX have?

    At the end of the period, Cumberland pharmaceuticals inc. (CPIX) held Total Cash and Cash Equivalents of 15.2M, accounting for 0.23 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does CPIX go with three margins increasing?

    In the latest report, Cumberland pharmaceuticals inc. (CPIX) did not achieve the “three margins increasing” benchmark, with a gross margin of 88.1%%, operating margin of -23.7%%, and net margin of -23.4%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess CPIX's profit trajectory and future growth potential.

  • Is CPIX's EPS continuing to grow?

    According to the past four quarterly reports, Cumberland pharmaceuticals inc. (CPIX)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -0.13. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of CPIX?

    Cumberland pharmaceuticals inc. (CPIX)'s Free Cash Flow (FCF) for the period is -456.66K, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 206.8% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of CPIX?

    The latest valuation data shows Cumberland pharmaceuticals inc. (CPIX) has a Price-To-Earnings (PE) ratio of -9.57 and a Price/Earnings-To-Growth (PEG) ratio of -0.04. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.